Key patents granted for Probiodrug’s pGlu-Abeta targeting monoclonal antibody program for the treatment of Alzheimer’s disease
Probiodrug to Attend and Present at European Conferences in March 2016
HALLE/SAALE, Germany, 28 January 2016 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that Dr Konrad Glund, Chief Executive Officer, and Dr Hendrik Liebers, Chief Financial Officer, are scheduled to attend and present at the following events:
(1) Petercam Healthcare Seminar
3 February 2016, Hotel Bloom, Brussels, Belgium
Dr Hendrik Liebers, CFO, to attend the event
8-9 February 2016, The Waldorf Astoria, New York, USA
Dr Konrad Glund, CEO, to present on 8 February at 3.30 pm EST in room Park South
The BIO CEO & Investor Conference is one of the largest investor conferences targeted at established and emerging publicly traded as well as select private biotech companies. The attendees include institutional investors, industry analysts, and senior biotechnology executives. The conference features plenary sessions, educational sessions focused on hot therapeutic areas and key business issues, company presentations, one-on-one meetings, and networking opportunities.
23 February 2016, The Millennium Hilton, 55 Church St, New York, NY 10007, United States
Dr Hendrik Liebers, CFO, to participate on the panel: Advances in Alzheimer’s disease, at 11.05 am EST
The 1st Annual Neuroscience BioPartnering & Investment Forum will focus on key areas of neurodegenerative diseases and pain management. The event brings buy and sell side analysts from investment banks and funds together with partnering executives from pharma. The Forum is expected to welcome around 200 delegates and 20 presenting companies. The event includes sessions on Deal Making, Investment, Public Markets as well as Panels on: Alzheimer’s disease, Parkinson’s disease and Lewy Body Dementia, neuropsychiatry & Pain Management and Orphan Diseases.
For more information, please contact:
Dr Konrad Glund, CEO
Mary Clark, Supriya Mathur, Alexia Faure
Tel: +44 (0) 203 440 5657
Notes to Editors:
About Probiodrug AG
Headquartered in Halle, Germany, Probiodrug AG (Euronext Amsterdam: PBD) is a biopharmaceutical company focused on the development of new therapeutic products for the treatment of Alzheimer’s disease.
Founded in 1997, the company successfully developed a novel therapeutic concept for diabetes – the DP4 inhibitors – which provided the basis for a novel class of antidiabetics – the gliptins. Its core capabilities are based on its long-standing expertise in the elucidation of the structure and function of enzymes involved in the modification of proteins and peptides, which play a central role in pathological conditions.
Today Probiodrug’s aim is to become a leading company in the development of Alzheimer’s disease treatments and to thereby provide a better life for Alzheimer’s disease patients. It has identified a new therapeutic concept linked to disease initiation and progression. The development approaches are targeting pyroglutamate-Abeta (pGlu-Abeta) as a therapeutic strategy to fight Alzheimer’s disease. The Company has medical use and composition of matter patents related to the inhibition of Glutaminyl Cyclase (QC) and anti-pGlu-Abeta- specific monoclonal antibodies, providing it, in the Company’s view, with a leading position in this field of research.
About Alzheimer’s disease
Alzheimer’s disease is a neurological disorder, which is the most common form of dementia, and ultimately leads to death. Because Alzheimer’s disease cannot be cured and is degenerative, the affected patients must increasingly rely on others for assistance. Today, over 46 million people worldwide currently live with the condition and this number is expected to increase to 132 million by 2050. Alzheimer’s also has an estimated, global societal cost of US$ 818 billion (World Alzheimer Report 2015).
Forward Looking Statements
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgment of Probiodrug AG as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.